As a biotech investor… this could very well be one of the most important articles you read this month.
MBRX has license agreements for anti-cancer drug candidates based on discoveries made at M. The first impression you will have when you begin your research on MBRX is that you will notice that the stock is trading near all-time lows, which is where the opportunity lies.
The Company recently released a corporate update that reveals some very interesting news regarding Annamycin and their Investigational New Drug IND application with the FDA.
The Company expects that the sponsor's IND will move forward in Physician-scientists at another major US cancer center have requested and Moleculin has agreed to supply them with WP for testing in a potential grant-funded clinical trial for children with Diffuse Intrinsic Pontine Gliomas DIPGa rare and very aggressive form of brain tumor.
Moleculin's COO is a man named Dr. When asked about Annamycin's potential, he responded with: In all my experience, Annamycin is one of the best drug development opportunities I've seen.
First off, Annamycin has shown little to no cardiotoxicity in over patients treated. It's important to understand that when treating AML patients with the currently approved drugs, including VYXEOS Celator's lead drug, which is now owned by Jazz Pharmaceuticals after their acquisition of Celatorcardiotoxicity is the number one dose limiting toxicity for oncologists. This means that they always have to monitor the patient's heart levels and adjust dosing accordingly when treating them for AML.
By having to adjust dosing based on cardiotoxicity levels, this severely limits the oncologist's ability to treat the patients properly. Since Annamycin has shown little to no cardiotoxicity in over patients, if approved, oncologists could treat their patients properly without the fear of creating life-threatening heart damage while they are trying to kill the cancer. Secondly, a laboratory study has suggested that Annamycin doesn't succumb to multidrug resistance. This means that one of the most common reasons for existing therapies to fail in AML patients may be overcome by Annamycin.
Like all other currently approved AML therapies, VYXEOS is also vulnerable to multidrug resistance, thus hindering the oncologist's ability to effectively treat the patient. Below is a really cool animation Moleculin did for their shareholders to visually show how Annamycin has been shown in a laboratory study to avoid the multidrug resistance pumps and how one of the lead drugs used in the VYXEOS formulation doesn't. This means that they didn't have 6-months to live, they literally had weeks to live and many of their organs were almost at failure due to the excessive amounts of chemotherapy they had received in those prior five treatments.
60 Second Binary Options
And, at the same time, putting none of those patients at risk for heart damage! The importance of this cannot be overstated, as we believe it makes Annamycin a potential game-changer in the treatment of AML patients. That is something that is extremely impressive and potentially disruptive if Annamycin is approved as a drug. All cancers are terrible, but AML is a very ugly disease which is very hard to treat and to fully understand the dire situation that these newly diagnosed AML patients face, it's best to put you in their shoes.
Let's say that you have received the sa rand us dollar exchange rate news that you have AML. As mentioned before, multidrug resistance means that your body's immune reliable forex signals provider begins to reject the drugs more and more each time it identifies the drugs the japanese stock market crash are being injected into your body.
To achieve the same results as the first treatment that you received, your oncologist will have to increase the dosage for each 60 seconds binary options trading websites india every treatment thereafter.
That might seem like an easy solution, how much money earned by dhoom 3 as your oncologist increases the dosage, he or she has to worry about the damage that is being done to your heart since these drugs are highly cardiotoxic.
For AML patients, bone marrow transplants mean life. As a newly diagnosed AML patient, you will quickly learn that you want to qualify for a bone marrow transplant to 60 seconds binary options trading websites india the best odds at survival. However, even though the drugs did their job at killing your cancer cells, they also did long-term damage to your heart potentially causing heart problems for you in the future.
This is a very important part for you to understand as this is where the rubber meets the road for AML patients. This just means that newly diagnosed patients will always receive approved first-line therapy federal reserve stock market manipulation. The problem with this scenario is that there are NO currently approved second-line therapies for AML patients.
But if you fail that again, then you are out of luck and on average you will be dead in 6-months. As we mentioned before, there are NO second-line therapies approved by the FDA. So, if you fail first-line, there are NO other approved options.
Weigand Omega | Page Not Found - Weigand Omega
VYXEOS will most likely be approved for first-line therapy for AML patients and Jazz Pharmaceutical shareholders will be very happy about this. The strategy that Moleculin has chosen is to seek approval from the FDA as a second-line therapy.
Best book for indian stock market beginners reason they have done this is because they believe it is the quickest and cheapest pathway to approval.
Because there are no currently approved drugs for second-line therapy for AML patients, the FDA has the ability to grant accelerated approval on the basis of fewer and smaller clinical trials where a drug has the potential to fill a significant unmet need. If the IND for Annamycin becomes effective, Moleculin would be about to begin their next clinical trial for Annamycin, which puts them on track to possibly getting their drug approved as the ONLY second-line therapy approved for AML patients!
As a relatively new public company, we look forward to see what happens with MBRX over the next months as they get underway on multiple clinical trials linux futures trading software free two different drugs! Copyright TRADING BIOTECH All Best option trading platform for beginners Reserved.
Moleculin Just Announced June 21, a Significant Discovery with the Potential to Treat Pancreatic Cancer! Click Here To Read The Press. HOW CAN ANNAMYCIN DISRUPT THE AML SPACE?
Binary Option Trading India Websites
BASED ON THE FACTS, MBRX SHOULD BE ON YOUR RADAR TODAY! Annamycin White Paper Annamycin and Children suffering from AML article Children and Leukemia Video Cardiotoxicity article Multidrug Resistance article Moleculin Management Nasdaq IPO Behind The Scenes Video Moleculin's Facebook Page.
The information contained in this corporate profile is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.
This corporate profile has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in this corporate profile. Individuals should assume that all information in this corporate profile is not trustworthy unless verified by their own independent research. Any individual who chooses to invest in any securities should do so with caution.
Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing. Subscribers are cautioned not to place undue reliance upon these forward looking statements. As of May 20,Hagens Media has received total compensation of fifty thousand dollars from Moleculin Biotech for the preparation, publication, and management of this corporate profile as well as other marketing and investor relations services.
Hagens Media and its principals currently hold zero shares in MBRX, but may buy or sell such shares at any time without notice.
This compensation and position constitute a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. We are committed to providing factual information on the companies that are profiled. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.
To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in this profile, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information.
We encourage you to invest carefully and read investment information available at the websites of the SEC and the Financial Industry Regulatory Authority "FINRA".